Empagliflozin

Patient

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

Targeted Gen 2 replacement answers for selected common questions; preserve other supported patient content.

patient-02 — Why might it be prescribed for me?

Established. Empagliflozin is used for several reasons. In adults, it can lower the chance of heart failure hospital stays, help slow some kidney disease, or lower heart-related death in people with type 2 diabetes and heart disease. It can also lower blood sugar in type 2 diabetes. Ask which reason applies to you. People may take it for heart or kidney benefit even when lowering blood sugar is not the main goal.

Sources: Jardiance US Prescribing Information (DailyMed), §1

patient-03 — What improvement should I expect?

Established. Some people need fewer hospital stays for heart failure or slower kidney disease decline while taking empagliflozin. The studies measured groups over months or years; they cannot promise what one person will feel. The medicine may not make you feel different day to day. Your care team can explain the goal for your condition and how it will be checked. Do not stop it just because you do not notice a change.

Sources: Jardiance US Prescribing Information (DailyMed), §§14.3–14.5; source; source

patient-05 — How will I know whether it is helping?

Established. Your care team may check blood sugar, kidney tests, blood pressure symptoms, and signs of infection. Jardiance makes urine sugar tests positive, so those tests should not be used to track your blood sugar. Tell your team if you feel dizzy when standing, cannot keep drinks down, or have new genital pain or sores on your feet. Ask which tests you need and when. The label does not set one schedule for everyone.

Sources: Jardiance US Prescribing Information (DailyMed), §§5.2–5.5,7

patient-06 — How does it work, in simple terms?

Established. Your kidneys normally return much of the sugar they filter back to your blood. Empagliflozin blocks a kidney carrier called SGLT2, so more sugar leaves in urine. This can lower blood sugar, but the medicine can also help some people with heart or kidney problems even when they do not have diabetes. Sugar loss alone does not explain all of those benefits. It can also make you urinate more.

Sources: Jardiance US Prescribing Information (DailyMed) §12.1

patient-07 — How much is usually taken, and how often?

Established. The usual adult Jardiance dose for heart or kidney protection is one 10 mg tablet each morning, with or without food. For extra blood-sugar lowering, the prescriber may raise it to 25 mg if you tolerate 10 mg. Do not change your dose yourself. Follow the pharmacy label and ask your prescriber or pharmacist if your tablets or directions look different. The right dose depends on why you take it.

Sources: Jardiance US Prescribing Information (DailyMed), §2.2

patient-12 — Can I stop when I feel better?

Established. Do not stop empagliflozin just because you feel better without asking your care team. Heart or kidney problems may not cause daily symptoms. If you have nausea, vomiting, belly pain, or deep breathing, stop the drug and get medical help right away, as the label says. For planned surgery or a long fast, ask your team to plan the label’s hold of at least three days beforehand, if possible. Ask when to start again.

Sources: Jardiance US Prescribing Information (DailyMed) §§2.3,5.1

patient-14 — Which symptoms need urgent help?

Established. Ketoacidosis can start with nausea, vomiting, belly pain, unusual tiredness, or deep or fast breathing. It can happen even if blood sugar is not very high. If these signs happen, stop Jardiance and get medical help right away. Get urgent help for fainting, trouble breathing, or severe pain and swelling near your genitals. Do not take Jardiance if you have had an allergy to empagliflozin or any tablet ingredient. Tell care staff when you last took it.

Sources: Jardiance US Prescribing Information (DailyMed) §§4,5.1,5.3,5.6

patient-18 — Will I need tests or monitoring?

Established. The care team may check kidney function before treatment and again when needed. If you take empagliflozin for blood sugar, its effect gets weaker as kidney function falls; the label does not recommend it for blood sugar control below eGFR 30. Heart and kidney studies included some people with eGFR 20. These are different treatment reasons. Ask your prescriber what your latest kidney test means for your own plan.

Sources: Jardiance US Prescribing Information (DailyMed), §§8.6,14.3–14.5

Caregiver

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

caregiver-02 — What changes should I look for?

Established. The medicine can help protect the heart or kidneys, even when blood sugar is not the reason it was started. It also makes more sugar and water leave in urine. Watch for dizziness when standing, unusual thirst, vomiting, belly pain, or new genital soreness. Write down when symptoms began and the last dose. Call the care team for advice during illness or poor eating; urgent breathing trouble, fainting, or severe weakness needs emergency help. Do not change another medicine on your own.

Sources: Jardiance US Prescribing Information (DailyMed), §§5.2–5.5

caregiver-03 — What is the correct routine?

Established. For most adults, the Jardiance label says to take one 10 mg tablet each morning. It can be taken with food or without it. A 25 mg dose is only for extra blood-sugar control, after the person tolerates 10 mg. Use the dose on their own pharmacy label. Keep the tablets in that labeled bottle and mark each dose if it is hard to remember. Ask the pharmacist before splitting, crushing, or mixing the tablet.

Sources: Jardiance US Prescribing Information (DailyMed), §2.2

caregiver-07 — What if they vomit after taking it?

Established. If the person throws up, cannot drink, or is not eating, call the care team for a sick-day plan. The team may say to pause Jardiance during a bad illness or long fast. The right plan depends on the reason for the drug and the other medicines. Nausea, throwing up, belly pain, or deep, fast breaths can be signs of a serious acid problem, even when blood sugar is not very high. Get urgent help for these signs.

Sources: Jardiance US Prescribing Information (DailyMed), §§5.1–5.3

caregiver-10 — How should a liquid dose be measured?

Uncertain. Jardiance comes as tablets. Its US label gives no liquid dose or way to measure a liquid. Do not crush or mix a tablet unless a pharmacist checks this exact product and gives safe steps. Other products with empagliflozin may have different forms, strengths, or tools. Keep the bottle and ask the pharmacist to confirm the product and dose before changing how it is given. This helps avoid giving too much or too little medicine.

Sources: Jardiance US Prescribing Information (DailyMed), §§3,16

caregiver-12 — Could side effects look like confusion or falls?

Established. Too little fluid or low blood pressure can cause dizziness, weakness, confusion, or a fall. The risk may be higher in an older person or someone who takes a water pill. Jardiance can make the person pass urine more often. Note new thirst, falls, faintness, or trouble drinking, and tell the care team if these begin or get worse. Do not assume sudden confusion is just a drug effect. Fainting or severe illness needs prompt care.

Sources: Jardiance US Prescribing Information (DailyMed), §5.2

caregiver-14 — Which symptoms require emergency help?

Established. Get urgent help for trouble breathing, fainting, or severe swelling. Also get help for a painful red area near the genitals, especially with fever or feeling very ill. Nausea, throwing up, belly pain, or deep breathing can also be signs of a serious problem, even when blood sugar is not very high. Bring the medicine list and say when the person last took Jardiance. These rare problems need quick care; do not wait for the next visit.

Sources: Jardiance US Prescribing Information (DailyMed), §§5.1,5.3,5.6

caregiver-16 — What changes during illness or dehydration?

Established. If the person is very ill, throwing up, or not eating or drinking, call the prescriber and ask if Jardiance should pause. Ask when it should start again. Before planned surgery or a long fast, the label says to stop the drug at least three days before, if possible. Start again only when the person is well and eating, as the care team says. Keep this plan with the medicine list so everyone can find it.

Sources: Jardiance US Prescribing Information (DailyMed), §§2.3,5.1

caregiver-17 — What should we record for the next appointment?

Established. A short note can help at the next visit. Write the dose and time, missed doses, dizziness, how much the person drinks, throwing up, genital soreness, foot sores, and blood sugar if asked. Jardiance makes sugar tests in urine come back positive, so those tests cannot track blood sugar. Bring the note and medicine bottles to the visit. Tell the care team about new foot pain, sores, or signs of infection as soon as you can.

Sources: Jardiance US Prescribing Information (DailyMed), §§5.5,7

Pharmacist

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

pharmacist-02 — Is the dose appropriate for this patient?

Established. For adults, the label dose for heart failure, chronic kidney disease, or cardiovascular-death risk in type 2 diabetes is 10 mg once each morning, with or without food. For additional glycemic control, 25 mg may be used only after tolerating 10 mg. Glycemic efficacy is reduced below eGFR 45, and use for glycemic control is not recommended below 30. HF/CKD trial evidence starts at eGFR 20; that does not establish routine initiation in dialysis.

Sources: Jardiance US Prescribing Information (DailyMed), §§2.2,8.6,14

pharmacist-04 — What adjustments apply in renal or hepatic impairment?

Established. The label does not recommend Jardiance for glycemic control when eGFR is below 30 mL/min/1.73 m²; glucose lowering is reduced below 45. HF and CKD trials enrolled down to eGFR 20, but trial continuation after decline is not evidence for routine initiation on dialysis. The label says it may be used in hepatic impairment; exposure rises as impairment worsens, and the label gives no hepatic dose table. For CKD, it excludes polycystic kidney disease and certain immunosuppression.

Sources: Jardiance US Prescribing Information (DailyMed), §§1,8.6–8.7,12.3,14.3–14.5

pharmacist-05 — What contraindications and allergy concerns matter?

Established. The label lists hypersensitivity to empagliflozin or any Jardiance excipient as a contraindication. It also says to assess and correct volume depletion before starting, especially in older adults, people with impaired kidney function, or those taking loop diuretics. Type 1 diabetes is not an indication for glycemic control because ketoacidosis risk rises. These boundaries differ: a contraindication is not the same as a warning, precaution, or population in which evidence is limited.

Sources: Jardiance US Prescribing Information (DailyMed), §§4,5.1,5.6

pharmacist-06 — Which drug interactions are important?

Established. Insulin and insulin secretagogues can raise hypoglycemia risk with Jardiance; the label says a lower dose of those agents may be needed. Diuretics can increase urine volume and volume-depletion risk. Lithium levels may fall, so monitor serum lithium more often during Jardiance initiation and dose changes. The drug also makes urine glucose tests positive, and 1,5-AG testing is unreliable; use other ways to assess glycemia. Check the full regimen before recommending a change.

Sources: Jardiance US Prescribing Information (DailyMed) §7

pharmacist-09 — What baseline and follow-up monitoring is needed?

Established. Check renal function and volume status before treatment and as clinically indicated, especially in older adults, people with impaired kidney function, or those using loop diuretics. Assess symptoms of volume depletion and genital or urinary infection. Urine glucose is expected and cannot monitor glycemic control during SGLT2 treatment; 1,5-AG is also unreliable. Use blood glucose or HbA1c as appropriate to the clinical question. The label does not prescribe one universal testing interval for every patient.

Sources: Jardiance US Prescribing Information (DailyMed), §§2.1,5.2,7

pharmacist-11 — What are the missed-dose instructions?

Established. If a dose is missed, the label says to take it as soon as possible and not to double the next dose. It does not give a cutoff for how close to the next dose is “too close,” so avoid adding an unsupported timing rule. If the patient is unsure what to do, confirm the missed-dose plan with the prescriber or pharmacist. For an extra dose or symptoms, use the label’s Poison Help contact or seek medical advice based on the amount and situation.

Sources: Jardiance US Prescribing Information (DailyMed) §§2.4,10

pharmacist-17 — What preparation, storage, and stability rules apply?

Established. Store Jardiance at 20–25°C (68–77°F); the label permits brief excursions from 15–30°C (59–86°F). It is supplied as 10 mg and 25 mg tablets. Check the tablet strength and the prescription directions before dispensing. The adult 10 mg dose covers heart failure, CKD, and cardiovascular-death risk in type 2 diabetes; 25 mg is only for extra glycemic control after tolerating 10 mg. Keep administration instructions separate from storage conditions.

Sources: Jardiance US Prescribing Information (DailyMed) §§2.2,3,16

pharmacist-19 — Which adverse reactions require escalation or reporting?

Established. Nausea, vomiting, abdominal pain, tiredness, or difficult breathing may signal ketoacidosis, even without very high glucose. The label says to stop Jardiance and seek immediate medical attention if these symptoms occur. Serious genital or urinary infection, pain or swelling near the genitals, and signs of a serious allergy also need prompt assessment. Ketoacidosis has occurred with glucose below 250 mg/dL. Ask about reduced food intake, illness, surgery, alcohol, and insulin changes, but do not delay urgent care.

Sources: Jardiance US Prescribing Information (DailyMed) §§5.1,5.3,5.6

Clinician

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

clinician-01 — Where does this drug fit in treatment?

Established. ADA 2026 recommends an SGLT2 inhibitor for people with type 2 diabetes and heart failure irrespective of A1C, and recommends an SGLT2 inhibitor or GLP-1 receptor agonist for CKD risk reduction. HF and CKD guidelines also place SGLT2 inhibitors in evidence-based care. Empagliflozin has randomized HF and CKD outcome evidence in people without diabetes. Select the indication and evidence population rather than treating it as only a glucose drug. The label’s kidney and glycemic eGFR thresholds differ.

Sources: ADA Standards of Care 2026, §9, Recommendations 9.7–9.10, source; AHA/ACC/HFSA 2022 HF Guideline, source; KDIGO 2024 CKD Guideline, source; Jardiance US Prescribing Information (DailyMed), §1

clinician-04 — How large is the absolute clinical benefit?

Established. In EMPEROR-Reduced, the primary composite of cardiovascular death or HF hospitalization occurred in 361/1,863 patients (19.4%) on empagliflozin and 462/1,867 (24.7%) on placebo over median 16 months; HR 0.75 (95% CI 0.65–0.86). The observed proportions differed by about 5.3 percentage points; the reciprocal is about 19 over that trial horizon. This is a composite in symptomatic HF with EF ≤40%, not a mortality-only effect or a universal individual NNT.

Sources: source

clinician-06 — How applicable is the trial population to my patient?

Established. EMPA-KIDNEY enrolled 6,609 people with eGFR 20–<45, or eGFR 45–<90 with UACR ≥200 mg/g. Over median 2.0 years, kidney-disease progression or cardiovascular death occurred in 432/3,304 (13.1%) with empagliflozin and 558/3,305 (16.9%) with placebo; HR 0.72 (95% CI 0.64–0.82). The observed proportions differed by about 3.8 percentage points for this composite and follow-up. It does not establish new treatment initiation in dialysis or every cause of CKD.

Sources: source

clinician-07 — What starting dose and titration are labeled?

Established. The label recommends 10 mg once each morning for adults treated for HF, CKD, or cardiovascular-death risk in type 2 diabetes. For additional glycemic control, increase to 25 mg only if 10 mg is tolerated. Glycemic benefit is diminished below eGFR 45 and use for glycemic control is not recommended below 30. HF/CKD trial inclusion extended to eGFR 20, but this is not the same as a glycemic threshold or evidence to initiate therapy in dialysis.

Sources: Jardiance US Prescribing Information (DailyMed), §§2.2,8.6

clinician-10 — What baseline assessment is needed?

Established. Before starting, assess renal function and volume status, and correct volume depletion. Review diuretic use, insulin or sulfonylurea therapy, prior ketoacidosis, genital infection risk, foot disease, and planned fasting or surgery. The label identifies hypersensitivity to empagliflozin or Jardiance excipients as a contraindication. It does not list a boxed warning. These checks support safe prescribing but do not replace the indication-specific assessment or a review of the full current label.

Sources: Jardiance US Prescribing Information (DailyMed), §§2.1,4,5.2

clinician-11 — Which outcomes and tests should be monitored?

Established. Follow the outcome relevant to the indication: glycemia for diabetes treatment, symptoms and clinical status for HF, and renal function and CKD progression measures for kidney disease. A modest early eGFR change can reflect the expected hemodynamic effect; interpret it with volume status and the clinical course. Do not use urine glucose to monitor glycemia because empagliflozin makes it positive. The label does not define one universal lab schedule for every indication or patient.

Sources: Jardiance US Prescribing Information (DailyMed), §§5.2,7,8.6,14

clinician-15 — Which interactions change management?

Established. Review insulin and insulin secretagogues because hypoglycemia may increase and dose reduction can be considered. Diuretics may add to urine volume and volume depletion. Lithium concentrations may decrease; monitor serum lithium more often during empagliflozin initiation and dose changes. Before planned surgery or prolonged fasting, withhold empagliflozin for at least three days if possible, then resume when clinically stable and eating. Ask about illness and reduced intake; ketoacidosis can occur below 250 mg/dL.

Sources: Jardiance US Prescribing Information (DailyMed), §§2.3,5.1,7

clinician-19 — What changes around surgery, procedures, or illness?

Established. The label advises withholding empagliflozin for at least three days before scheduled surgery or procedures involving prolonged fasting, if possible. Resume when the patient is clinically stable and oral intake has resumed. Urinary glucose loss usually persists for about three days after stopping, and postmarketing reports describe persistence beyond six days and up to two weeks. These intervals describe glucosuria, not a guaranteed time for every other pharmacologic effect to end.

Sources: Jardiance US Prescribing Information (DailyMed), §§2.3,5.1,12.2

Nurse

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

nurse-02 — What should I check before administration?

Established. Before giving the dose, verify the patient, Jardiance product, prescribed strength, timing, ability to take oral medication, and any hold order. Check whether the patient is fasting, vomiting, or scheduled for surgery, and confirm the sick-day plan if intake is poor. For adults, the labeled dose for HF, CKD, or cardiovascular-death risk is 10 mg in the morning. A 25 mg dose is for added glycemic control only after tolerating 10 mg.

Sources: Jardiance US Prescribing Information (DailyMed), §§2.2–2.3

nurse-03 — Which vital signs and laboratory results matter?

Established. Check renal function and volume status as ordered, and observe blood pressure symptoms, dizziness on standing, urine output changes, and hydration concerns. For diabetes, use blood glucose or HbA1c rather than urine glucose; Jardiance is expected to make urine glucose positive. Ask about vomiting, abdominal pain, unusual tiredness, and deep breathing because ketoacidosis may occur without very high glucose. Use the patient’s indication and local protocol to guide escalation; the label sets no universal monitoring schedule.

Sources: Jardiance US Prescribing Information (DailyMed), §§2.1,5.2,7

nurse-04 — When should I clarify or hold a dose?

Established. Clarify a dose when the patient is unable to eat or drink, is vomiting, has a planned procedure with fasting, or reports ketoacidosis symptoms. For scheduled surgery or prolonged fasting, the label says to stop empagliflozin at least three days beforehand if possible. Do not independently restart it after a prolonged hold; the patient should be clinically stable and eating again. Follow the prescriber’s order and local escalation rules for urgent symptoms.

Sources: Jardiance US Prescribing Information (DailyMed), §§2.3,5.1

nurse-09 — When should I reassess the patient?

Established. Reassess according to the care plan and sooner if symptoms or status change; the label gives no single reassessment interval for every patient. Check whether the patient is dizzy when standing, drinking less, urinating more, or developing genital or urinary symptoms. For vomiting, belly pain, unusual tiredness, or difficult breathing, promptly assess and escalate for possible ketoacidosis even if glucose is not very high. Document the finding, timing, intake, and action taken.

Sources: Jardiance US Prescribing Information (DailyMed), §§5.1–5.3; local clinical escalation protocol

nurse-11 — What common adverse effects should I watch for?

Established. Common reactions include urinary tract infection and female genital yeast infection; increased urination may also occur. Ask about burning, pain, itching, discharge, fever, thirst, or dizziness and report new symptoms. Severe infection can need urgent care. The label also warns about volume loss and lower-limb problems. Check feet for sores, ulcers, new pain, or infection, especially with prior foot disease, and follow the care plan. Do not tell patients that every symptom is caused by Jardiance.

Sources: Jardiance US Prescribing Information (DailyMed) §§5.2,5.3,5.5,6.1

nurse-12 — What requires immediate escalation?

Established. Escalate nausea, vomiting, stomach pain, unusual tiredness, or difficult breathing because these may indicate ketoacidosis, even if glucose is below 250 mg/dL. Urgent assessment is also needed for severe genital pain or swelling, fever with infection symptoms, fainting, or a serious allergic reaction. Jardiance is formally contraindicated with hypersensitivity to empagliflozin or any product ingredient. Follow emergency protocol and report the last dose, food or fluid intake, and other diabetes medicines.

Sources: Jardiance US Prescribing Information (DailyMed) §§4,5.1,5.3,5.6

nurse-14 — What if a dose is missed, refused, or vomited?

Established. For a missed dose, the label says to take it as soon as possible and not to double the next dose. It does not give a cutoff for how close to the next dose is too close, so do not add an unsupported timing rule. For vomiting or an extra dose, follow the prescriber’s or poison center’s case-specific advice. During illness with poor intake, confirm the sick-day plan. Before surgery or prolonged fasting, withhold for at least three days if possible and restart when stable and eating.

Sources: Jardiance US Prescribing Information (DailyMed) §§2.3–2.4,10

nurse-18 — What should teach-back check?

Established. Teach that urine glucose can be positive because the medicine sends more glucose into urine; it is not a reliable blood sugar test. Review when to seek help for vomiting, belly pain, deep breathing, severe genital symptoms, fainting, or new foot sores. Ask the patient to explain that Jardiance should be withheld for at least three days before surgery or prolonged fasting, if possible, and restarted when clinically stable and eating again. Document teach-back and open questions.

Sources: Jardiance US Prescribing Information (DailyMed) §§2.3,5.1,7

Student

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

student-03 — What is the mechanism of action?

Established. Empagliflozin blocks SGLT2 in the proximal tubule, reducing reabsorption of filtered glucose and sodium. More glucose reaches urine; reduced proximal sodium uptake also changes distal sodium delivery and tubuloglomerular feedback. The drug does not directly stimulate insulin release. SGLT2 handles most filtered glucose reabsorption, while SGLT1 retrieves much of the remainder downstream. This explains glycosuria and a possible early hemodynamic eGFR dip, but not the full causal pathway for heart and kidney outcome benefits.

Sources: Jardiance US Prescribing Information (DailyMed), §12.1

student-05 — How is it absorbed, distributed, metabolized, and eliminated?

Established. After oral dosing, peak plasma concentration occurs at about 1.5 hours and the terminal half-life is about 12.4 hours. Plasma protein binding is 86.2%; apparent steady-state volume of distribution was estimated at 73.8 L based on population PK analysis. Empagliflozin is mainly glucuronidated; the label says no major metabolites were detected in human plasma. About 54% of a radiolabeled dose was recovered in urine and 41% in feces, including unchanged drug and metabolites. These data do not remove the need to consider renal population limits.

Sources: Jardiance US Prescribing Information (DailyMed) §12.3

student-09 — What are the key adverse effects?

Established. Important adverse effects include genital and urinary infections, volume depletion, ketoacidosis, and hypoglycemia when combined with insulin or insulin secretagogues. The label also warns about lower-limb events and serious genitourinary infections, including Fournier’s gangrene. In pooled adult trials, female genital mycotic infection was 1.5% on placebo, 5.4% on 10 mg, and 6.4% on 25 mg. In children, hypoglycemia risk was higher, even without insulin. Group rates do not predict one person’s risk.

Sources: Jardiance US Prescribing Information (DailyMed) §§5.1–5.5,6.1,8.4

student-12 — Which interactions matter most?

Established. Empagliflozin has few expected enzyme-mediated interactions because it does not inhibit or induce CYP450 enzymes and is mainly glucuronidated. Insulin or secretagogues may increase hypoglycemia, diuretics may increase volume loss, and lithium levels may decrease. UGT induction, such as by rifampicin, has not been evaluated. The label considers interactions with P-gp substrate drugs unlikely and does not expect effects on OAT3 or OATP substrate drugs at relevant levels; it does not make the same statement for BCRP.

Sources: Jardiance US Prescribing Information (DailyMed) §§7,12.3

student-13 — What monitoring is needed, and why?

Established. Monitor the outcome that matches the treatment reason: HbA1c or blood glucose for glycemic control, kidney tests for CKD, and heart-failure status for HF. Check renal function and volume status before starting and as clinically needed. Urine glucose tests are not useful for glycemic monitoring because empagliflozin makes them positive; 1,5-AG testing is unreliable too. The label does not set one test schedule for all patients. This separates a drug effect from treatment benefit.

Sources: Jardiance US Prescribing Information (DailyMed) §§2.1,5.2,7,8.6

student-14 — How does organ impairment affect dosing?

Established. The label distinguishes glycemic efficacy from cardiorenal trial evidence. Glucose lowering is reduced when eGFR is below 45 mL/min/1.73 m², and use for glycemic control is not recommended below 30. HF and CKD outcome trials enrolled some patients at eGFR 20. The label says Jardiance may be used in hepatic impairment, while measured exposure rises with severity. These are different treatment contexts; trial continuation after decline or dialysis is not a universal initiation recommendation.

Sources: Jardiance US Prescribing Information (DailyMed) §§8.6–8.7,12.3,14.3–14.5

student-15 — How does it differ from related drugs?

Established. Empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin inhibit SGLT2, but their labels, studied populations, doses, and outcome evidence are not interchangeable. A canagliflozin amputation finding should not be assigned to every member of the class. For empagliflozin, pooled lower-limb event rates were 4.3 on placebo and 5.0 on empagliflozin per 1,000 patient-years; HR 1.05 (95% CI 0.81–1.36). CKD-trial rates were 2.9 on placebo and 4.3 on treatment. This does not prove no risk; foot care remains advised.

Sources: Jardiance US Prescribing Information (DailyMed) §5.5

student-19 — What evidence established its clinical role?

Established. Clinical role is supported by separate outcome trials. EMPA-REG found fewer primary cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. EMPEROR-Reduced and EMPEROR-Preserved found fewer cardiovascular-death or heart-failure-hospitalization composite events in symptomatic HF groups with different ejection fractions. EMPA-KIDNEY found fewer kidney-progression or cardiovascular-death events in selected CKD. These trials support distinct labeled uses; their endpoints and follow-up differ, so do not treat them as one pooled result.

Sources: Jardiance US Prescribing Information (DailyMed), §§1,14.3–14.5; source; source; source; source

Scientist

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

scientist-01 — What is the primary target and its evidence base?

Established. Empagliflozin inhibits human SGLT2, the proximal-tubule sodium-glucose cotransporter. The pharmacology links target inhibition to reduced glucose reabsorption and urinary glucose excretion. An inhibitor-bound cryo-EM structure of human SGLT2–MAP17 places empagliflozin in the sugar-binding region and extracellular vestibule, stabilizing an outward-open state. The structure supports target-level plausibility; it does not by itself establish how much each renal or systemic pathway contributes to clinical outcomes.

Sources: Jardiance US Prescribing Information (DailyMed), §12.1; Niu et al., Nature 2022, PMID 34880493, source

scientist-02 — Is the proposed mechanism causal or associated?

Established. Small familial renal glucosuria studies link SLC5A2 loss-of-function to persistent glucose loss in urine, supporting SGLT2’s role in kidney glucose reabsorption. Severe cases also showed sodium loss, mild volume depletion, and signs of renin–aldosterone activation. These small inherited-disease cohorts do not prove that genetic loss is always harmless or that it has the same effects as time-limited drug treatment. Randomized trials establish treatment outcomes in their studied groups, but not the pathway causing each benefit.

Sources: Calado et al. 2006, PMID 16518345, source; Calado et al. 2008, PMID 18622023, source; Jardiance US Prescribing Information (DailyMed) §12.1

scientist-03 — How can target engagement be measured?

Established. Direct target engagement can be measured in a transporter assay by testing SGLT2 activity with and without empagliflozin. Urinary glucose excretion is a proximal pharmacodynamic readout of reduced renal glucose reabsorption, not a direct measure of drug binding to SGLT2. Downstream measures such as sodium handling, eGFR change, or hematocrit answer different questions. Prespecify assays and controls; a post hoc link between a biomarker and outcome does not prove mediation. Outcome trials establish benefit in studied groups, not the pathway causing it.

Sources: Jardiance US Prescribing Information (DailyMed) §12.1; Grempler et al. PMID 21985634, source

scientist-04 — How selective is it at relevant exposures?

Established. The label and Grempler et al. describe empagliflozin as selective for SGLT2 over SGLT1. The retained abstract reports an SGLT2 IC50 of 3.1 nM and high selectivity, but does not supply a numeric ratio in the text checked here. An assay selectivity value is not a clinical safety margin at every tissue concentration. Interpret it with assay conditions, free exposure, species, and transporter expression. The exact ratio needs the full assay table.

Sources: Jardiance US Prescribing Information (DailyMed), §12.1; Grempler et al., PMID 21985634, source; [VERIFY] full assay table for exact ratio

scientist-06 — What tissue exposures are known?

Uncertain. The label describes plasma pharmacokinetics and urinary and fecal recovery, but it does not establish quantitative empagliflozin concentrations across human heart, kidney, or other tissues. Urinary recovery is not a direct measure of drug concentration at a tissue target. A human tissue-distribution claim would need an appropriate sampling or validated imaging study with assay methods and exposure context. Keep plasma exposure, renal pharmacology, and tissue concentration as separate evidence categories.

Sources: Jardiance US Prescribing Information (DailyMed), §12.3

scientist-10 — Which experimental models are suitable?

Probable. Suitable models depend on the pathway being tested. A human SGLT2–MAP17 cell system can assess transporter inhibition, while animal or human renal-hemodynamic studies can examine downstream kidney responses. A model of cardiac benefit needs a relevant heart-failure context and should separate direct myocardial effects from changes in loading or kidney function. No single model reproduces the full clinical setting. State what the system measures, its species and disease limits, and avoid treating an in-vitro result as outcome proof.

Sources: Jardiance US Prescribing Information (DailyMed), §12.1; Niu et al., PMID 34880493, source; Cherney et al., PMID 24334175, source

scientist-15 — Which biomarkers track engagement or response?

Established. Candidate biomarkers include urinary glucose excretion for SGLT2 pharmacodynamics, eGFR slope for kidney function, hematocrit, and measures of volume or renal hemodynamics. Each reflects a different part of the response and none alone proves the mechanism of outcome benefit. Urine glucose is not a glycemic-control test in treated patients. A biomarker study should prespecify the measure, sampling time, and relation to exposure and endpoint, then distinguish target engagement from downstream association.

Sources: Jardiance US Prescribing Information (DailyMed) §§5.2,7,12.1–12.2,14.4–14.5

scientist-20 — Which next experiment would reduce uncertainty?

Uncertain. A useful next study would prespecify one candidate mediator, measure exposure and target engagement, and include a perturbation or rescue that can test whether the mediator is necessary. The model should match the proposed pathway and include controls for changes in glucose, volume, and renal function. Clinical trials already establish outcome effects for empagliflozin in selected populations, but they do not resolve the full mechanism. Do not present a proposed experiment as evidence that the mechanism is already proven.

Sources: Jardiance US Prescribing Information (DailyMed), §12.1; proposed experiment based on unresolved mechanisms

Chemist

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

chemist-01 — What is the structure and active molecular form?

Established. Empagliflozin is a small-molecule C-aryl glucoside. Jardiance tablets contain parent empagliflozin, not a prodrug or a named salt. Its formula is C23H27ClO7 and its molecular weight is 450.91 g/mol. The carbon-linked glucose-like group, chlorinated aromatic region, and substituted tetrahydrofuran form its molecular scaffold. Those identity details do not establish that any one group alone causes selectivity or clinical benefit.

Sources: PubChem CID 11949646, source; Jardiance US Prescribing Information (DailyMed) §11

chemist-02 — Which functional groups matter for activity?

Probable. Empagliflozin has a carbon-linked C-glucoside, while phlorizin has an oxygen-linked O-glucoside. The C–C bond is expected to resist cleavage by intestinal glucosidases better than an O-glycosidic bond; this is a structure-based inference, not a stability result in the label or Niu structure paper. The inhibitor-bound structure shows the sugar-like region in the SGLT2 site and the aglycone in the outer vestibule. Do not infer potency from the pose. [VERIFY] primary comparative hydrolysis study.

Sources: Jardiance US Prescribing Information (DailyMed), §11; Niu et al., PMID 34880493, source; [VERIFY] primary hydrolysis study

chemist-03 — How does stereochemistry affect the drug?

Established. The marketed structure contains the specified (1S) configuration and a [(3S)-tetrahydrofuran-3-yl]oxy substituent. Include those stereochemical labels when describing identity; a flat drawing without wedges can hide the specified form. The label chemical name and PubChem structure establish the marketed configuration. They do not quantify how much either stereocenter contributes to binding or exposure. That needs a controlled comparison with defined stereoisomers in suitable assays.

Sources: Jardiance US Prescribing Information (DailyMed) §11; PubChem CID 11949646, source

chemist-05 — What supports the proposed binding mode?

Established. PDB 7VSI is the cryo-EM structure of human SGLT2–MAP17 bound to empagliflozin at 2.95 Å resolution. The inhibitor occupies the glucose-recognition region and extends into the extracellular vestibule while the transporter is outward-open. This is direct structural evidence of the complex, not a docking-only prediction. The static structure does not quantify binding kinetics, prove one state dominates in vivo, or establish which pathway causes clinical outcomes.

Sources: Niu et al., Nature 2022, PMID 34880493, source; PDB 7VSI, source

chemist-07 — How do ionization and pKa affect behavior?

Uncertain. A formulation-relevant pKa should be reported with the exact measurement method, solvent, temperature, and whether the value is measured or predicted. The current prescribing information does not provide a verified empagliflozin pKa in its clinical pharmacology section. Do not infer a physiological ionization state from the neutral structure alone. If pKa is needed for a formulation or permeability claim, retrieve a primary experimental determination or a clearly identified validated prediction and label it accordingly.

Sources: Jardiance US Prescribing Information (DailyMed), §12.3; [VERIFY] primary pKa measurement and conditions

chemist-08 — What is known about solubility and dissolution?

Established. The label describes empagliflozin as very slightly soluble in water. It gives no numeric value here and no full pH-solubility profile or dissolution rate. A development comparison needs the method, temperature, pH, solid form, particle size, and test media. Do not turn a qualitative label phrase into a concentration or claim that water solubility alone explains oral exposure; the label reports oral pharmacokinetic data separately.

Sources: Jardiance US Prescribing Information (DailyMed) §11

chemist-10 — Which transporters influence disposition?

Established. Empagliflozin is a substrate of the efflux transporters P-gp and BCRP. The label considers it unlikely to cause interactions with P-gp substrate drugs, but does not make the same statement for BCRP substrates. It is also a substrate of the uptake transporters OAT3, OATP1B1, and OATP1B3, not OAT1 or OCT2, and does not inhibit these uptake transporters at relevant plasma levels. Keep efflux and uptake findings distinct from labeled clinical interactions.

Sources: Jardiance US Prescribing Information (DailyMed) §12.3

chemist-11 — What are the main metabolic pathways?

Established. The label says no major empagliflozin metabolites were detected in human plasma; three glucuronide conjugates were the most abundant metabolites, each below 10% of total drug-related material. After a radiolabeled dose, about 54% of radioactivity was recovered in urine and 41% in feces. Those totals include unchanged drug and metabolites, not only unchanged-drug clearance. Keep metabolism, mass balance, and renal pharmacology distinct.

Sources: Jardiance US Prescribing Information (DailyMed) §12.3

Investor / Diligence Analyst

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

analyst-03 — How large is the reachable patient market?

Established. CMS reported about 1.883 million Part D users and $8.84 billion in gross covered-drug spending for Jardiance in 2023. That is a real utilization signal, but it is not a count of all patients who could use the drug or manufacturer net revenue. Empagliflozin has separate uses in diabetes, heart failure, and CKD, with overlap between groups. To estimate a reachable market, split users by indication, eligibility, payer, and year using current claims rather than adding broad disease totals.

Sources: CMS 2026 negotiated-price fact sheet, source; [VERIFY] current indication-level claims

analyst-05 — What meaningful differentiation is demonstrated?

Established. The evidence is indication-specific: EMPA-REG studied type 2 diabetes with established cardiovascular disease; EMPEROR-Reduced and -Preserved studied symptomatic heart failure across EF ranges; EMPA-KIDNEY studied CKD with defined eGFR and albuminuria entry criteria. The label reflects distinct cardiovascular, HF, CKD, and glycemic uses. This breadth differentiates the product, but does not mean every trial endpoint applies to every labeled patient or that empagliflozin is superior to every alternative.

Sources: Jardiance US Prescribing Information (DailyMed), §1; source; source; source; source

analyst-06 — How strong is the human efficacy evidence?

Established. Across four trials, the label reports different primary outcomes and populations. EMPA-REG’s three-point MACE was 10.5% versus 12.1% over median 3.1 years (HR 0.86). EMPEROR-Reduced’s CV-death/HF-hospitalization composite was 19.4% versus 24.7% over median 16 months (HR 0.75). EMPEROR-Preserved was 13.8% versus 17.1% over median 26.2 months (HR 0.79). EMPA-KIDNEY was 13.1% versus 16.9% over median 2 years (HR 0.72). Do not pool these rates as one effect.

Sources: Jardiance US Prescribing Information (DailyMed), §§14.3–14.5; source; source; source; source

analyst-07 — Is the demonstrated benefit clinically meaningful?

Established. Trial results show clinically relevant absolute differences in specified groups, alongside relative hazard ratios. For example, EMPA-KIDNEY’s primary composite differed by 3.8 percentage points over median two years; that crude reciprocal is about 26, but it is not a universal patient NNT. EMPEROR-Reduced’s difference was 5.3 points over median 16 months. Absolute benefit depends on baseline risk, endpoint, follow-up, and competing treatment. Do not translate a hazard ratio directly into a price or population-wide event reduction.

Sources: Jardiance US Prescribing Information (DailyMed), §§14.3–14.5; source; source

analyst-08 — How credible are the trial design and endpoints?

Established. The four outcome programs used randomized, blinded, placebo-controlled designs, but enrolled different populations and chose different composite endpoints. EMPA-REG enrolled people with type 2 diabetes and established cardiovascular disease; the two EMPEROR trials enrolled symptomatic HF by ejection fraction; EMPA-KIDNEY used eGFR and albuminuria criteria. Each trial supports its own endpoint and follow-up. A diligence comparison should examine protocol, comparator background therapy, missing data, endpoint components, and label fit rather than rank hazard ratios alone.

Sources: Jardiance US Prescribing Information (DailyMed), §§14.3–14.5; primary trial reports linked in 14.3–14.5

analyst-09 — Which safety findings could limit adoption?

Established. Safety diligence should include genital and urinary infections, volume depletion, ketoacidosis, and lower-limb events. Across four outcome trials, pooled amputation rates were 4.3 per 1,000 patient-years on placebo and 5.0 on empagliflozin (HR 1.05; 95% CI 0.81–1.36). In the CKD trial, rates were 2.9 on placebo and 4.3 on empagliflozin. This estimate does not prove no risk. The label advises foot care and monitoring, especially with prior foot disease, peripheral artery disease, or diabetes.

Sources: Jardiance US Prescribing Information (DailyMed) §§5.1–5.5

analyst-16 — What patents, exclusivity, and freedom-to-operate issues apply?

Uncertain. A current exclusivity assessment needs a dated FDA Orange Book search for Jardiance and any listed patents or regulatory exclusivities, plus relevant patent-family review. The presence of generic empagliflozin products should be verified by exact application and launch status rather than inferred from the molecule’s age. This FAQ does not establish freedom to operate for a new formulation, combination, or use. [VERIFY] Search the live Orange Book and ANDA records, then confirm applicable court or settlement dates before modeling entry.

Sources: Jardiance US Prescribing Information (DailyMed), [VERIFY] relevant label section; [VERIFY] FDA Orange Book and ANDA records

analyst-18 — What would support reimbursement and pricing?

Established. CMS set Jardiance’s 2026 negotiated Medicare price at $197 per 30-day-equivalent supply, 66% below the weighted average 2023 list price of $573. CMS also reported about 1.883 million Part D users and $8.84 billion in gross covered-drug spending in 2023; that is not manufacturer net revenue. These figures describe different years and measures. They do not establish current commercial net price, formulary access, or adoption. Check current plan rules before updating the model.

Sources: CMS 2026 negotiated-price fact sheet, source; [VERIFY] current plan formularies and claims

General

Questions for this perspective

This packet does not replace the existing questions for this perspective. Use the current guide for those answers; the expanded explanation above is new.